n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Mesothelioma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK | 1 |
1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Mesothelioma
Article | Year |
---|---|
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Specificity; Cetuximab; ErbB Receptors; Flow Cytometry; Humans; Isothiocyanates; Mesothelioma; Mice; Molecular Targeted Therapy; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |